286 related articles for article (PubMed ID: 30201411)
21. Long noncoding RNA lncTCF7, induced by IL-6/STAT3 transactivation, promotes hepatocellular carcinoma aggressiveness through epithelial-mesenchymal transition.
Wu J; Zhang J; Shen B; Yin K; Xu J; Gao W; Zhang L
J Exp Clin Cancer Res; 2015 Oct; 34():116. PubMed ID: 26452542
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of brachyury contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma.
Du R; Wu S; Lv X; Fang H; Wu S; Kang J
J Exp Clin Cancer Res; 2014 Dec; 33(1):105. PubMed ID: 25499255
[TBL] [Abstract][Full Text] [Related]
23. HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition.
Xu J; Zhang X; Wang H; Ge S; Gao T; Song L; Wang X; Li H; Qin Y; Zhang Z
Biomed Pharmacother; 2017 Apr; 88():421-429. PubMed ID: 28122307
[TBL] [Abstract][Full Text] [Related]
24. STAT3 cooperates with Twist to mediate epithelial-mesenchymal transition in human hepatocellular carcinoma cells.
Zhang C; Guo F; Xu G; Ma J; Shao F
Oncol Rep; 2015 Apr; 33(4):1872-82. PubMed ID: 25653024
[TBL] [Abstract][Full Text] [Related]
25. Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling.
Yin X; Zhang BH; Zheng SS; Gao DM; Qiu SJ; Wu WZ; Ren ZG
J Hematol Oncol; 2015 Mar; 8():23. PubMed ID: 25879771
[TBL] [Abstract][Full Text] [Related]
26. Cancer-associated Fibroblasts induce epithelial-mesenchymal transition
Jia C; Wang G; Wang T; Fu B; Zhang Y; Huang L; Deng Y; Chen G; Wu X; Chen J; Pan Y; Tai Y; Liang J; Li X; Hu K; Xie B; Li S; Yang Y; Chen G; Zhang Q; Liu W
Int J Biol Sci; 2020; 16(14):2542-2558. PubMed ID: 32792856
[TBL] [Abstract][Full Text] [Related]
27. Small hepatitis B virus surface antigen promotes malignant progression of hepatocellular carcinoma via endoplasmic reticulum stress-induced FGF19/JAK2/STAT3 signaling.
Wu S; Ye S; Lin X; Chen Y; Zhang Y; Jing Z; Liu W; Chen W; Lin X; Lin X
Cancer Lett; 2021 Feb; 499():175-187. PubMed ID: 33249195
[TBL] [Abstract][Full Text] [Related]
28. Role of IQGAP3 in metastasis and epithelial-mesenchymal transition in human hepatocellular carcinoma.
Shi Y; Qin N; Zhou Q; Chen Y; Huang S; Chen B; Shen G; Jia H
J Transl Med; 2017 Aug; 15(1):176. PubMed ID: 28810875
[TBL] [Abstract][Full Text] [Related]
29. High expression of forkhead box protein C2 is associated with aggressive phenotypes and poor prognosis in clinical hepatocellular carcinoma.
Shimoda Y; Ubukata Y; Handa T; Yokobori T; Watanabe T; Gantumur D; Hagiwara K; Yamanaka T; Tsukagoshi M; Igarashi T; Watanabe A; Kubo N; Araki K; Harimoto N; Katayama A; Hikino T; Sano T; Ogata K; Kuwano H; Shirabe K; Oyama T
BMC Cancer; 2018 May; 18(1):597. PubMed ID: 29801468
[TBL] [Abstract][Full Text] [Related]
30. Serum SALL4 is a novel prognosis biomarker with tumor recurrence and poor survival of patients in hepatocellular carcinoma.
Han SX; Wang JL; Guo XJ; He CC; Ying X; Ma JL; Zhang YY; Zhao Q; Zhu Q
J Immunol Res; 2014; 2014():262385. PubMed ID: 24860834
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway.
Xu Q; Liu X; Liu Z; Zhou Z; Wang Y; Tu J; Li L; Bao H; Yang L; Tu K
Mol Cancer; 2017 Jun; 16(1):103. PubMed ID: 28606154
[TBL] [Abstract][Full Text] [Related]
32. Downregulation of RFX1 predicts poor prognosis of patients with small hepatocellular carcinoma.
Liu Y; Jiang P; Wang G; Liu X; Luo S
Eur J Surg Oncol; 2018 Jul; 44(7):1087-1093. PubMed ID: 29764705
[TBL] [Abstract][Full Text] [Related]
33. Astragaloside IV inhibits cell migration and viability of hepatocellular carcinoma cells via suppressing long noncoding RNA ATB.
Li Y; Ye Y; Chen H
Biomed Pharmacother; 2018 Mar; 99():134-141. PubMed ID: 29331759
[TBL] [Abstract][Full Text] [Related]
34. TMPRSS4 facilitates epithelial-mesenchymal transition of hepatocellular carcinoma and is a predictive marker for poor prognosis of patients after curative resection.
Wang CH; Guo ZY; Chen ZT; Zhi XT; Li DK; Dong ZR; Chen ZQ; Hu SY; Li T
Sci Rep; 2015 Jul; 5():12366. PubMed ID: 26190376
[TBL] [Abstract][Full Text] [Related]
35. IL-6, through p-STAT3 rather than p-STAT1, activates hepatocarcinogenesis and affects survival of hepatocellular carcinoma patients: a cohort study.
Kao JT; Feng CL; Yu CJ; Tsai SM; Hsu PN; Chen YL; Wu YY
BMC Gastroenterol; 2015 Apr; 15():50. PubMed ID: 25908103
[TBL] [Abstract][Full Text] [Related]
36. miR-345 inhibits tumor metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT pathway in hepatocellular carcinoma.
Yu M; Xue H; Wang Y; Shen Q; Jiang Q; Zhang X; Li K; Jia M; Jia J; Xu J; Tian Y
Int J Oncol; 2017 Mar; 50(3):975-983. PubMed ID: 28098858
[TBL] [Abstract][Full Text] [Related]
37. Expression of interleukin-17 associated with disease progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection.
Du WJ; Zhen JH; Zeng ZQ; Zheng ZM; Xu Y; Qin LY; Chen SJ
Diagn Pathol; 2013 Feb; 8():40. PubMed ID: 23448394
[TBL] [Abstract][Full Text] [Related]
38. Increased Six1 expression in macrophages promotes hepatocellular carcinoma growth and invasion by regulating MMP-9.
Zhang Y; Wang S; Liu Z; Yang L; Liu J; Xiu M
J Cell Mol Med; 2019 Jul; 23(7):4523-4533. PubMed ID: 31044528
[TBL] [Abstract][Full Text] [Related]
39. Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.
Wang G; Chen JH; Qiang Y; Wang DZ; Chen Z
World J Gastroenterol; 2015 Apr; 21(13):3983-93. PubMed ID: 25852285
[TBL] [Abstract][Full Text] [Related]
40. As an independent prognostic factor, FAT10 promotes hepatitis B virus-related hepatocellular carcinoma progression via Akt/GSK3β pathway.
Liu L; Dong Z; Liang J; Cao C; Sun J; Ding Y; Wu D
Oncogene; 2014 Feb; 33(7):909-20. PubMed ID: 23812429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]